TCI GENE Inc.

6879 · TWO · Healthcare / Biotechnology

35.50TWD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close35.50

Open35.50

Day Range35.50 – 35.50

52-Week Range32.35 – 41.05

Volume10

Market Cap918.11M

P/E (TTM)18.26

Forward P/E0.00

EPS1.90

Dividend Yield0.00%

Beta0.28

50-Day Avg34.93

200-Day Avg35.90

About

TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-derived mesenchymal stem cells, natural killer immune cells, and immune cell storage programs. In addition, the company manufactures and sells testing reagents, health food, and beauty products; and health and nutritional supplements. TCI GENE Inc. was founded in 2011 and is based in Taipei, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
HeadquartersNo. 185, Gangqian Road, Taipei, Taiwan, 11494, Taiwan
Websitehttps://www.tci-gene.com

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	432.22M	424.02M	333.86M	347.54M	273.61M
Growth (%)	-	-1.90%	-21.26%	+4.10%	-21.27%
Cost of Revenue	192.79M	180.66M	159.24M	143.47M	121.02M
Gross Profit	239.43M	243.36M	174.62M	204.07M	152.59M
Gross Margin	55.40%	57.39%	52.30%	58.72%	55.77%
Operating Expense	125.86M	152.26M	168.60M	148.30M	133.51M
Operating Income	113.57M	91.10M	6.02M	55.77M	19.07M
Operating Margin	26.28%	21.48%	1.80%	16.05%	6.97%
EBITDA	-	120.63M	25.89M	81.85M	52.35M
EBITDA Margin	-	28.45%	7.76%	23.55%	19.13%
Net Income	92.45M	72.14M	11.67M	56.31M	40.57M
Net Income Margin	21.39%	17.01%	3.50%	16.20%	14.83%
R&D	59.46M	62.33M	45.62M	34.13M	33.68M
R&D as % of Total Revenue	13.76%	14.70%	13.67%	9.82%	12.31%
Interest Expense	835.00K	852.00K	1.18M	495.00K	1.40M
Interest Expense % of Total Revenue	0.19%	0.20%	0.35%	0.14%	0.51%

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	560.31M	1.16B	1.17B	1.10B	1.01B
Total Liabilities	169.44M	143.17M	155.55M	101.29M	98.64M
Total Equity	380.20M	1.01B	986.51M	974.73M	890.51M
Cash	326.19M	932.74M	696.05M	98.43M	250.69M

Cash Flow

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	119.18M	110.35M	17.85M	56.97M	151.33M
Capital Expenditure	23.42M	15.29M	3.17M	2.66M	417.00K
Free Cash Flow	95.76M	95.06M	14.68M	54.30M	150.91M
Dividends Paid	-	53.65M	52.92M	26.46M	52.92M
FCF to OCF	80.35%	86.14%	82.26%	95.32%	99.72%
Dividend Paid to FCF	-	56.43%	360.40%	48.72%	35.06%

Key Statistics & Ratios

Market Cap918.11M

Enterprise Value154.34M

Trailing P/E18.26

Forward P/E0.00

Price / Sales3.65

Price / Book1.10

EPS1.90

Book Value34.56

Revenue (TTM)251.39M

Gross Profit (TTM)144.99M

EBITDA33.72M

Profit Margin20.14%

Operating Margin14.62%

Return on Equity5.55%

Return on Assets1.69%

Shares Outstanding26.46M

Shares Float3.99M

Beta0.28

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio105.26%